Loading clinical trials...
Loading clinical trials...
A Phase 1 Study of ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies.
Conditions
Interventions
ICP-248
Azacitidine
Locations
18
United States
Yale University, Yale Cancer Center
New Haven, Connecticut, United States
NYU Langone Health
New York, New York, United States
St Vincent's Hospital
Sydney, New South Wales, Australia
Royal Perth Hospital
Perth, Western Australia, Australia
Anhui Provincial Hospita
Hefei, Anhui, China
Peking University People's Hospital
Beijing, Beijing Municipality, China
Start Date
December 18, 2024
Primary Completion Date
June 1, 2027
Completion Date
January 1, 2028
Last Updated
April 13, 2026
NCT06465953
NCT06859424
NCT07347171
NCT07254312
NCT02143830
NCT06398457
Lead Sponsor
Beijing InnoCare Pharma Tech Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions